JonesTrading Initiates Coverage on Evaxion A/S with Buy Rating

JonesTrading has initiated coverage of Evaxion A/S, a clinical-stage biotechnology company based in Copenhagen, Denmark, with a research report published on March 5, 2024. The firm rated the stock as a “buy” and set a price target of $10.00. This positive outlook comes amidst various analyses from other financial institutions, indicating a mix of sentiments regarding the stock’s performance.

In a report released on Monday, Lake Street Capital revised its price target for Evaxion A/S from $11.00 to $9.00, while maintaining a “buy” rating. On February 19, Maxim Group also began coverage of the company, setting a price objective of $10.00 with a “buy” recommendation. Meanwhile, HC Wainwright reaffirmed its “buy” rating and issued a higher target price of $16.00 for Evaxion.

Conversely, Weiss Ratings provided a more cautious perspective, restating a “sell (d-)” rating on the stock in a report issued on January 9. Currently, five research analysts favor a buy position, while one analyst has a sell rating, leading to an overall average rating of “Moderate Buy” and an average price target of $11.00, according to MarketBeat.com.

Recent Financial Performance and Market Activity

Evaxion A/S recently released its quarterly earnings data on March 5, reporting an earnings per share (EPS) of $0.30. Analysts are forecasting a projected EPS of -0.15 for the current year. The stock has shown a significant increase, rising by 8.0% following the earnings announcement.

In terms of institutional investment, hedge funds and other institutional investors have adjusted their holdings in Evaxion. Wesbanco Bank Inc. acquired a new stake valued at $48,000 during the fourth quarter. Similarly, Northwestern Mutual Wealth Management Co. invested $38,000, while SmartHarvest Portfolios LLC purchased shares worth $72,000. Institutional investors now hold approximately 11.04% of the company’s stock.

About Evaxion A/S

Evaxion A/S specializes in developing immunotherapies and vaccines through its proprietary artificial intelligence-based computational immunology platform. The company employs advanced machine learning and deep learning algorithms to identify and optimize antigen targets for therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the heart of Evaxion’s operations is its AI platform, which processes extensive datasets of genomic, proteomic, and immunological information to predict immune-stimulating epitopes. This innovative approach positions Evaxion at the forefront of biotechnology, emphasizing the potential for significant contributions to medical advancements.

As the company continues to navigate its path in the biotechnology sector, investors and analysts will closely monitor its performance and developments in the coming months.